Sanofi India Ltd stock (INE058A01010): Shares steady as investors await next earnings update

Sanofi India Ltd shares on the NSE held broadly steady on 06/02/2026, with investors in India focusing on the next earnings catalysts after the latest quarterly figures and ongoing portfolio realignment in the domestic pharmaceuticals market.

Sanofi India Ltd shares traded broadly unchanged on the National Stock Exchange of India on 06/02/2026, as market participants in India assessed the latest quarterly performance and awaited fresh company-specific catalysts in the pharmaceuticals space, according to The Economic Times as of 06/02/2026.

The stock recently changed hands around INR 4,229 on the NSE, compared with a previous close of approximately INR 4,173, implying a modest gain over the most recent trading sessions, according to The Economic Times as of 06/02/2026. The company is part of the broader Indian pharmaceuticals and healthcare sector, which remains closely watched by domestic investors on both the NSE and BSE.

As of: 06/02/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Sanofi
• Sector/industry: Pharmaceuticals and healthcare
• Headquarters/country: Mumbai, India
• Core markets: India with selected exports to other emerging markets
• Key revenue drivers: Branded prescription drugs, diabetes therapies, consumer healthcare products and specialty pharmaceuticals in India
• Home exchange/listing venue: National Stock Exchange of India (SANOFI), BSE (500674)
• Trading currency: INR

Sanofi India Ltd: core business model

Sanofi India Ltd focuses on supplying a mix of prescription medicines, vaccines and consumer healthcare brands to the Indian market, with revenues largely underpinned by therapies in diabetes, cardiovascular care and other chronic disease segments as well as over-the-counter products tailored to local demand.

Latest quarterly results for Sanofi India Ltd at a glance

The most recent available quarterly figures for Sanofi India Ltd relate to the fourth quarter and full year 2024, which were detailed in a company filing released in early 2025, according to the investor relations section of the company website as of 05/2025. In that period, the company reported year-on-year growth in revenue and profitability, reflecting contributions from key chronic therapies and its consumer healthcare portfolio in India.

According to the same filing, management highlighted continued focus on portfolio optimization in the Indian market, including emphasis on core prescription and consumer brands and disciplined cost control measures. The quarterly communication also referenced broader strategic alignment with the global Sanofi group's priorities, including sharpening focus on select therapeutic areas and adjusting the product mix in India to support sustainable margins.

Conclusion

Sanofi India Ltd shares have been trading in a relatively tight range on the NSE, with investors in India digesting prior quarterly numbers and monitoring developments in the domestic pharmaceuticals market. The latest reported quarter showed growth in key therapies and highlighted the groups ongoing efforts to streamline its Indian portfolio. How prescription demand, regulatory dynamics and competitive pressures in India evolve ahead of the next earnings release is likely to shape sentiment on the stock over the coming months.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.